Analysts Offer Insights on Healthcare Companies: Steris (STE), Arcellx Inc (ACLX) and BioCryst (BCRX)
There’s a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Steris (STE – Research Report), Arcellx Inc (ACLX – Research Report) and BioCryst (BCRX – Research Report) with bullish sentiments.
Claim 50% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Steris (STE)
Piper Sandler analyst Jason Bednar maintained a Buy rating on Steris today and set a price target of $300.00. The company’s shares closed last Thursday at $261.64.
According to TipRanks.com, Bednar is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Steris has an analyst consensus of Moderate Buy, with a price target consensus of $291.00, an 11.5% upside from current levels. In a report issued on January 25, KeyBanc also maintained a Buy rating on the stock with a $291.00 price target.
See the top stocks recommended by analysts >>
Arcellx Inc (ACLX)
In a report released today, Geoff Meacham from Citi reiterated a Buy rating on Arcellx Inc, with a price target of $110.00. The company’s shares closed last Thursday at $68.26.
According to TipRanks.com, Meacham is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Arcellx Inc with a $113.46 average price target, which is a 67.7% upside from current levels. In a report issued on January 21, Canaccord Genuity also maintained a Buy rating on the stock with a $130.00 price target.
BioCryst (BCRX)
RBC Capital analyst Brian Abrahams maintained a Buy rating on BioCryst today and set a price target of $13.00. The company’s shares closed last Thursday at $6.67.
According to TipRanks.com, Abrahams is a 4-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for BioCryst with a $19.70 average price target, which is a 195.8% upside from current levels. In a report issued on January 15, TipRanks – Google also upgraded the stock to Buy with a $7.50 price target.
